Status: Recruiting
"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL
evaluate the efficacy and safety of "Selinexor+pegaspargase+dexamethasone" in early stage NK/ T-cell lymphoma
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Mingzhi ZhangUpdated: Jul 14, 2025Locations: 1
Eligibility criteria
Age 18-70 years old, ECOG score 0-2; (including those aged 18 and 70); [+9]
Refuse to collect blood samples; [+12]